Enerpac Tool
EPAC
Precision Drilling
PDS
Halozyme Therapeutics
HALO
Workday
WDAY
Lantheus
LNTH
US Stock MarketDetailed Quotes
OPTN OptiNose
- 9.170
- 0.0000.00%
Close Mar 25 16:00 ET
- 9.100
- -0.070-0.76%
Post 18:15 ET
92.84MMarket Cap-2.11P/E (TTM)
9.217High9.140Low111.44KVolume9.140Open9.170Pre Close1.02MTurnover1.60%Turnover RatioLossP/E (Static)10.12MShares22.35052wk High-2.26P/B63.97MFloat Cap4.81552wk Low--Dividend TTM6.98MShs Float450.000Historical High--Div YieldTTM0.84%Amplitude4.815Historical Low9.163Avg Price1Lot Size
About OptiNose Company
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
Company Profile
SymbolOPTN
Company NameOptiNose
Listing DateOct 13, 2017
Issue Price16.00
Founded2000
CEODr. Ramy A. Mahmoud, M.D.
MarketNASDAQ
Employees132
Fiscal Year Ends12-31
Address777 Township Line Road,Suite 300
CityYardley
ProvincePennsylvania
CountryUnited States of America
Zip Code19067
Phone1-267-364-3500
Websitehttp://www.optinose.com
Company Executives
- Name
- Position
- Salary
- Dr. Ramy A. Mahmoud, M.D.
- Chief Executive Officer and Director
- 2.41M
- Michael F. Marino, III,
- Chief Legal Officer and Corporate Secretary
- 1.32M
- P. Terence Kohler, Jr
- Chief Financial Officer
- --
- Paul Spence, Jr
- Chief Commercial Officer
- 664.02K
- Anthony J. Krick
- Vice President, Finance and Chief Accounting Officer
- --
- R. John Fletcher
- Chairman of the Board
- 120.22K
- Wilhelmus C. M. Groenhuysen
- Independent Director
- 100.92K
- Sandra L. Helton
- Independent Director
- 103.42K
- Kyle Dempsey
- Independent Director
- 90.92K
- Tomas J. Heyman
- Independent Director
- 96.88K
- Dr. Eric Bednarski
- Independent Director
- 88.42K